Unconfigured Ad

Collapse

DNBSEQ-G400 from Complete Genomics: Latest Sequencing Technologies—Part 5

Collapse
X
Collapse
  •  

  • DNBSEQ-G400 from Complete Genomics: Latest Sequencing Technologies—Part 5

    Complete Genomics (an MGI company) released the DNBSEQ-G400 into the U.S. market this summer. DNBSEQ-G400 is a benchtop sequencer that uses MGI’S DNA Nanoball sequencing technology (DNBSEQ) that boasts low index hopping, low amplification bias, and low PCR amplification error accumulation. In addition, the instrument is capable of using an improved antibody-based chemistry, CoolMPS sequencing reagent, that reduces errors and improves the sequencing quality.
    DNBSEQ-G400
    Image of DNBSEQ-G400 (courtesy of MGI)


    Read type and length
    DNBSEQ-G400 is a short-read sequencer with a variety of read lengths and options, including SE50, SE100, SE400, PE100, PE150, PE200, and PE300. The run times vary from 13 to 58 hours depending on the selected flow cell, read lengths, and cycle kit.

    Flow cell/SMRT cell options
    There are two flow cell options, FCS and FCL, and users have the ability to run one or two independent flow cells per run. The FCS flow cell comes equipped with two lanes and the FCL has a total of four lanes. Each of the lanes can be loaded independently. There are also two options (StandardMPS and CoolMPS) for sequencing reagents. The StandardMPS can be used with any flow cell type, but the CoolMPS can only be used with the FCL flow cell.

    Data output
    The DNBSEQ-G400 can produce 55–1440 Gb of data per run, depending on the reagent type, read lengths, flow cell types, and number of flow cells used. The expected number of reads varies from 300M–550 M reads with a single FCS flow cell to 1500–2000 M reads with a single FCL flow cell.

    Analysis options
    Barcode demultiplexing and FASTQ generation are completed on the machine and are accounted for in the run times. Secondary analysis can be completed using external analysis tools or done with MGI’s MegaBOLT bioinformatics analysis accelerator. MegaBOLT includes existing framework for analysis of whole genome sequencing, whole exome sequencing, and panel sequencing with germline or somatic data.

    Common applications
    ● Microbial detection
    ● Single-cell sequencing
    ● Cancer panels
    ● Whole exome and genome sequencing
    ● 16S sequencing

    Release date
    Officially released in the U.S. in August, DNBSEQ-G400 is currently available for use, while three other sequencers are pending for release in the coming year (DNBSEQ-E25, DNBSEQ-T7, and DNBSEQ-T10x4). Sequencers and supplies from Complete Genomics (MGI) may have different availabilities and release schedules for customers in other countries.

    Highlights
    ● Customizable sequencing with many options for flow cells, read lengths, and reagent type.
    ● Low PCR error amplification, low amplification bias, and low index hopping.
    ● Wide range of available applications along with streamlined analysis from MegaBOLT bioinformatics software.
    ● Shorter time from sequencing to FASTQ generation.
    ● Improved base calling and reduced molecular scarring with CoolMPS reagent.

    To compare sequencing technologies please visit Biocompare
      Please sign into your account to post comments.

    About the Author

    Collapse

    seqadmin Benjamin Atha holds a B.A. in biology from Hood College and an M.S. in biological sciences from Towson University. With over 9 years of hands-on laboratory experience, he's well-versed in next-generation sequencing systems. Ben is currently the editor for SEQanswers. Find out more about seqadmin

    Latest Articles

    Collapse

    • Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Working...